418 related articles for article (PubMed ID: 27226573)
1. Different Soluble Forms of the Interleukin-6 Family Signal Transducer gp130 Fine-tune the Blockade of Interleukin-6 Trans-signaling.
Wolf J; Waetzig GH; Chalaris A; Reinheimer TM; Wege H; Rose-John S; Garbers C
J Biol Chem; 2016 Jul; 291(31):16186-96. PubMed ID: 27226573
[TBL] [Abstract][Full Text] [Related]
2. Minimal interleukin 6 (IL-6) receptor stalk composition for IL-6 receptor shedding and IL-6 classic signaling.
Baran P; Nitz R; Grötzinger J; Scheller J; Garbers C
J Biol Chem; 2013 May; 288(21):14756-68. PubMed ID: 23564454
[TBL] [Abstract][Full Text] [Related]
3. A soluble form of the interleukin-6 family signal transducer gp130 is dimerized via a C-terminal disulfide bridge resulting from alternative mRNA splicing.
Wolf J; Waetzig GH; Reinheimer TM; Scheller J; Rose-John S; Garbers C
Biochem Biophys Res Commun; 2016 Feb; 470(4):870-6. PubMed ID: 26809098
[TBL] [Abstract][Full Text] [Related]
4. The balance of interleukin (IL)-6, IL-6·soluble IL-6 receptor (sIL-6R), and IL-6·sIL-6R·sgp130 complexes allows simultaneous classic and trans-signaling.
Baran P; Hansen S; Waetzig GH; Akbarzadeh M; Lamertz L; Huber HJ; Ahmadian MR; Moll JM; Scheller J
J Biol Chem; 2018 May; 293(18):6762-6775. PubMed ID: 29559558
[TBL] [Abstract][Full Text] [Related]
5. Estrogen downregulates gp130 expression in HUVECs by regulating ADAM10 and ADAM17 via the estrogen receptor.
Zhou M; Dai W; Cui Y; Li Y
Biochem Biophys Res Commun; 2020 Mar; 523(3):753-758. PubMed ID: 31952790
[TBL] [Abstract][Full Text] [Related]
6. Cleavage Site Localization Differentially Controls Interleukin-6 Receptor Proteolysis by ADAM10 and ADAM17.
Riethmueller S; Ehlers JC; Lokau J; Düsterhöft S; Knittler K; Dombrowsky G; Grötzinger J; Rabe B; Rose-John S; Garbers C
Sci Rep; 2016 May; 6():25550. PubMed ID: 27151651
[TBL] [Abstract][Full Text] [Related]
7. Alternative intronic polyadenylation generates the interleukin-6 trans-signaling inhibitor sgp130-E10.
Sommer J; Garbers C; Wolf J; Trad A; Moll JM; Sack M; Fischer R; Grötzinger J; Waetzig GH; Floss DM; Scheller J
J Biol Chem; 2014 Aug; 289(32):22140-50. PubMed ID: 24973212
[TBL] [Abstract][Full Text] [Related]
8. Influence of humanized anti-IL-6R antibody, tocilizumab on the activity of soluble gp130, natural inhibitor of IL-6 signaling.
Hashizume M; Mihara M
Rheumatol Int; 2009 Feb; 29(4):397-401. PubMed ID: 18802703
[TBL] [Abstract][Full Text] [Related]
9. Structure-guided optimization of the interleukin-6 trans-signaling antagonist sgp130.
Tenhumberg S; Waetzig GH; Chalaris A; Rabe B; Seegert D; Scheller J; Rose-John S; Grötzinger J
J Biol Chem; 2008 Oct; 283(40):27200-7. PubMed ID: 18650419
[TBL] [Abstract][Full Text] [Related]
10. Meprin Metalloproteases Generate Biologically Active Soluble Interleukin-6 Receptor to Induce Trans-Signaling.
Arnold P; Boll I; Rothaug M; Schumacher N; Schmidt F; Wichert R; Schneppenheim J; Lokau J; Pickhinke U; Koudelka T; Tholey A; Rabe B; Scheller J; Lucius R; Garbers C; Rose-John S; Becker-Pauly C
Sci Rep; 2017 Mar; 7():44053. PubMed ID: 28276471
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor.
Garbers C; Thaiss W; Jones GW; Waetzig GH; Lorenzen I; Guilhot F; Lissilaa R; Ferlin WG; Grötzinger J; Jones SA; Rose-John S; Scheller J
J Biol Chem; 2011 Dec; 286(50):42959-70. PubMed ID: 21990364
[TBL] [Abstract][Full Text] [Related]
12. The IL-6-neutralizing sIL-6R-sgp130 buffer system is disturbed in patients with type 2 diabetes.
Aparicio-Siegmund S; Garbers Y; Flynn CM; Waetzig GH; Gouni-Berthold I; Krone W; Berthold HK; Laudes M; Rose-John S; Garbers C
Am J Physiol Endocrinol Metab; 2019 Aug; 317(2):E411-E420. PubMed ID: 31237452
[TBL] [Abstract][Full Text] [Related]
13. The interleukin-6 receptor Asp358Ala single nucleotide polymorphism rs2228145 confers increased proteolytic conversion rates by ADAM proteases.
Garbers C; Monhasery N; Aparicio-Siegmund S; Lokau J; Baran P; Nowell MA; Jones SA; Rose-John S; Scheller J
Biochim Biophys Acta; 2014 Sep; 1842(9):1485-94. PubMed ID: 24878322
[TBL] [Abstract][Full Text] [Related]
14. IL-6 trans-signaling system in intra-amniotic inflammation, preterm birth, and preterm premature rupture of the membranes.
Lee SY; Buhimschi IA; Dulay AT; Ali UA; Zhao G; Abdel-Razeq SS; Bahtiyar MO; Thung SF; Funai EF; Buhimschi CS
J Immunol; 2011 Mar; 186(5):3226-36. PubMed ID: 21282511
[TBL] [Abstract][Full Text] [Related]
15. Functional expression of a biologically active fragment of soluble gp130 as an ELP-fusion protein in transgenic plants: purification via inverse transition cycling.
Lin M; Rose-John S; Grötzinger J; Conrad U; Scheller J
Biochem J; 2006 Sep; 398(3):577-83. PubMed ID: 16716147
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-6 and its receptors: a highly regulated and dynamic system.
Wolf J; Rose-John S; Garbers C
Cytokine; 2014 Nov; 70(1):11-20. PubMed ID: 24986424
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-11-driven gastric tumourigenesis is independent of trans-signalling.
Balic JJ; Garbers C; Rose-John S; Yu L; Jenkins BJ
Cytokine; 2017 Apr; 92():118-123. PubMed ID: 28160627
[TBL] [Abstract][Full Text] [Related]
18. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses.
Jostock T; Müllberg J; Ozbek S; Atreya R; Blinn G; Voltz N; Fischer M; Neurath MF; Rose-John S
Eur J Biochem; 2001 Jan; 268(1):160-7. PubMed ID: 11121117
[TBL] [Abstract][Full Text] [Related]
19. Soluble gp130 prevents interleukin-6 and interleukin-11 cluster signaling but not intracellular autocrine responses.
Lamertz L; Rummel F; Polz R; Baran P; Hansen S; Waetzig GH; Moll JM; Floss DM; Scheller J
Sci Signal; 2018 Oct; 11(550):. PubMed ID: 30279168
[TBL] [Abstract][Full Text] [Related]
20. Activation of Toll-like Receptor 2 (TLR2) induces Interleukin-6 trans-signaling.
Flynn CM; Garbers Y; Lokau J; Wesch D; Schulte DM; Laudes M; Lieb W; Aparicio-Siegmund S; Garbers C
Sci Rep; 2019 May; 9(1):7306. PubMed ID: 31086276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
